Tilray Brands (TLRY) Q1 2027 earnings review
Tilray's sales rose 23%, but the company lost $40 million
Tilray, which sells cannabis and craft beer and distributes medicines in Europe, grew through an acquisition while its profit shrank. Sales rose 23%, but BrewDog, the beer business it bought in the spring, supplied almost all of the increase. Chief executive Irwin D. Simon said scale now brings stronger margins, but costs rose faster than gross profit.
| Sales outside the beverage business | $155.7M +1.2% from a year ago, by our math; total sales $257.1M, +23% |
|---|---|
| Beverage sales, including BrewDog | $101.5M +82% from a year ago |
| Profit before interest, tax, depreciation and one-offs | $9.2M $10.2M a year ago |
| Full-year outlook for that profit | Unchanged $68–75 million; middle of the range: 17% growth |
⚖️ Verdict: 🔴 Bearish
The story got worse because Tilray kept its full-year profit target after a quarter that fell short of the pace it needs. By our math, profit before interest, tax, depreciation and one-offs must grow about 22% over the rest of the year. One positive: cannabis and beverages each earned a higher gross margin.
The question now is whether the businesses Tilray owned a year ago still grow. If they do, profit can catch up with the target; if not, the target depends on one strong fourth quarter. Second-quarter sales outside beverages will tell.
🐂 Bull Case
Beverage Margin Rose After the BrewDog Purchase
Tilray bought BrewDog, a British craft brewer, in the spring, and this is the first full quarter with it. Beverage sales rose 82% to $101.5 million, and the group said BrewDog made a profit.
- Beverage gross margin: 41.4%, up from 38.3% a year ago
- Beverage gross profit: $42.0 million, up from $21.3 million
- Share of group sales: 39%, up from 27%
This matters because beverages now earn more gross profit than any other Tilray business. But the release does not say how the older US beer brands sold, and those brands were shrinking before the purchase.
What to watch: BrewDog's own sales and profit in the quarterly filing. A stated figure would show whether the acquired brewer or the older brands produced the margin gain.
Cannabis Outside Canada Grew 21%
Tilray grows cannabis in Canada, Portugal and Germany and sells medical cannabis in other countries. Those foreign sales rose 21% to $16.2 million.
- Cannabis gross margin: 39.2%, up from 36.1% a year ago
- International share of cannabis sales before excise tax: 22%, up from 15%
- International sales against the prior quarter: down 40%, from $27.2 million
The margin gain matters because Tilray has said foreign medical sales earn more than Canadian ones. One caution: late export permits made the same quarter a year ago weak, so the comparison was easy.
What to watch: international cannabis sales next quarter, against $20.2 million a year earlier. Growth on that harder comparison would show that demand, not permit timing, drives the business.
Positives this quarter didn't test
Three parts of the growth case got no new numbers in the earnings release. Each one has a date or a disclosure that will test it.
- Carlsberg beer in the US: chief executive Irwin D. Simon said the brewer partnered with Tilray to "begin producing and selling its iconic brands in the U.S. market starting January 1, 2027".
- Quebec cannabis site: management said last quarter that product from the restarted facility would reach stores in September; second-quarter Canadian sales will show it.
- Owning the medical supply chain in Europe: Tilray has a UK clinic and pharmacy business and a German medicine distributor; a published profit margin for medical cannabis abroad would test the claim.
🐻 Bear Case
Costs Rose Faster Than Gross Profit
Simon, the chief executive, said Tilray now has "the ability to convert scale into stronger margins, greater efficiency and sustainable, profitable growth". The quarter's numbers show the opposite below the gross profit line, where overhead and advertising grew faster than sales.
- Overhead (general and administrative costs): 22.4% of sales, up 2.8 percentage points
- Marketing and promotion: 6.1% of sales, up 1.3 percentage points
- Core profit (earnings before interest, tax, depreciation and one-offs) as a share of sales: 3.6%, down from 4.9%
This matters because the extra gross profit did not turn into profit. Overhead and marketing together rose $22.1 million, by our math, more than the $20.0 million gain in gross profit. So core profit fell 10%.
Management said last quarter that the first three quarters earn about half of annual profit, in even parts. By our math that pointed to at least $11.3 million now, and Tilray stayed below it even after adding back fuel surcharges.
What to watch: general and administrative costs as a share of sales next quarter. A share near 22% again would mean the full-year profit target rests almost entirely on the fourth quarter.
Canadian Cannabis Sales Fell 16%
Canada is where Tilray sells most of its cannabis, mainly to adult recreational users. Those sales fell 16% before excise tax, and that pulled the whole cannabis business down 13%.
- Canadian medical cannabis: down 23%, to $4.7 million
- Wholesale cannabis: down 84%, to $0.7 million
- Cannabis gross profit: down 5%, to $22.0 million
This matters because Canada has now shrunk for two quarters, and the fall is getting faster. The release gives no reason, so readers cannot tell lost customers from lower prices.
What to watch: Canadian adult-use sales next quarter, when management has said cannabis from its restarted Quebec site reaches stores. A third decline with new supply would point to weaker demand.
Tilray Sold Shares to Cover Its Cash Outflow
Tilray said its balance sheet "remains strong" and that it cut debt by $42 million since the fiscal year began. The cash flow statement shows where the money came from: the business used cash, and new shares replaced it.
- Free cash flow (operating cash flow minus investment): negative $27.4 million
- Cash from selling new shares: $22.3 million
- Cash spent repaying long-term debt: $5.8 million
- Shares outstanding: 144.9 million, up 10% in three months
This matters because existing owners pay for the shortfall through a smaller stake in the group. The average share count was 26% higher than a year ago, so each share's claim on any future profit shrank by about a fifth.
Most of the debt reduction did not use cash either. By our math, convertible notes fell $20.3 million with no matching cash repayment, which points to payment in shares.
What to watch: the share count next quarter, and how Tilray settles the $59.2 million of notes now due within a year. Share sales near the size of the cash outflow again would confirm that new shares fund the business.
Risks this quarter didn't answer
Seven standing concerns got no new numbers in the earnings release. The quarterly filing or a later quarter will give the reading for each one.
- Goodwill: $752.4 million, unchanged; the annual test in the fourth quarter is the next reading.
- Cannabis prices abroad: no price figure in the release; the filing's discussion of international cannabis will show whether price cuts continued.
- Older US beer brands: no sales figure apart from BrewDog; a split of beverage sales would show whether they still shrink.
- US rules on cannabis and hemp drinks: nothing new in the release; a court or federal decision would move this.
- US tariffs on Canadian goods: the wellness business, which sells hemp foods, earned a 28.5% gross margin against 32.0%; the filing should give the cause.
- Lawsuits: litigation costs were $0.8 million; the large claims against Tilray remain open.
- Export permit timing: it can move international cannabis sales between quarters; the release does not say whether permits affected this one.
👓 Other Themes
Fuel Surcharges Took $1.7 Million From Profit
Tilray said global fuel surcharges cost about $1.7 million in the quarter, after $2.3 million in the prior one. Adding the charge back, core profit, which is earnings before interest, tax, depreciation and one-offs, would have been about $10.9 million by our math. That is 7% above last year's figure, so fuel explains the fall but not the gap to the full-year target.
💲 Other KPIs
Tilray's medicine distribution business grew 14% from a year ago, but growth has slowed from 35% two quarters ago. Its gross margin stayed at 11%, the lowest of the four businesses, so this growth adds little profit.
Inventory rose 9% in three months while sales fell 9% from the prior quarter. The build used $27.8 million of cash, the largest single drain on operating cash flow. Inventory stood 16% above its level a year ago.
Cash and securities fell $13.2 million in three months and stand 16% below the level a year ago. Tilray said it ended the quarter with more cash than debt. On balance-sheet values that margin is about $17 million by our math; the release does not state the figure.
🔮 Guidance
Unchanged. The plan still has this profit rising about 17% this year. By our math, that leaves about 22% growth for the rest of the year, after a 10% fall in the first quarter. Tilray said results are "more weighted toward the second half of the fiscal year, with results strengthening significantly in the fourth quarter". Last year the group finished just below the bottom of its range.
❓ Key Questions
How much did BrewDog sell and earn this quarter?
Beverage sales rose 82%, but the release does not separate BrewDog from the older US beer brands. Without that split, nobody outside Tilray can tell whether those brands still shrink or which profit measure BrewDog met.
Does Tilray still plan for over $1 billion of sales?
Simon set that floor last quarter, and this release does not repeat it. By our math the floor needs only about 5% growth over the rest of the year, far less than this quarter's 23%.
How much of the $42 million debt cut used cash?
The balance sheet shows debt about $25 million lower at the end of August, and the cash flow statement shows $5.8 million of repayments. Tilray has not said how it will settle the convertible notes now due within a year.
What profit margin does cannabis earn outside Canada?
The growth case rests on foreign medical cannabis earning more than Canadian sales. Tilray has never published that margin, so the shift toward foreign sales cannot yet be checked against profit.
Why did Canadian cannabis sales fall 16%?
The release reports the decline without a cause. Lost market share, lower prices and product redirected to export would each mean something different for next quarter.